Safety & Initial Performance of the MediSieve Magnetic Haemofiltration

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is a single centre, prospective, non-randomised healthy volunteer study to be undertaken at University College Hospital London. The study will be used to demonstrate the safe use of the MediSieve blood filtration system in healthy volunteers prior to undertaking clinical trials on patients with relevant pathologies.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03853005` - Effect of High volumeHemodiafiltration on Lung Oxygenation and Mechanics	N/A
	Completed	`NCT05713188` - Clinical Investigation of the Safety of the MediSieve Magnetic Haemofiltration System in Healthy Volunteers	Phase 1

NCT number	NCT03786536
Study type	Interventional
Source	MediSieve Limited
Contact
Status	Withdrawn
Phase	N/A
Start date	June 1, 2020
Completion date	December 31, 2020

Safety and Initial Performance of the MediSieve Magnetic Haemofiltration System

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms